Bioatla Inc（BCAB）資訊與事件

$1.735

-0.776 (-44.75%)收盤時

BCAB 資訊

9.508-06NASDAQ.COM

Context Therapeutics Reports Wider Loss in Q2 2026

9.503-31seekingalpha

BioAtla Reports Q4 Loss and Announces Share Consolidation

8.503-31seekingalpha

BioAtla Announces 50-for-1 Share Consolidation Plan

9.503-06Benzinga

Smith & Wesson Exceeds Q3 Earnings Expectations

4.503-02Newsfilter

BioAtla Initiates Strategic Review to Maximize Shareholder Value

2.002-09Benzinga

STMicroelectronics Shares Rise 4.3% in Pre-Market Trading

9.501-16seekingalpha

Healthcare Stocks with Strong Earnings Momentum Earn A+ EPS Revision Grades

2.001-06NASDAQ.COM

Alumis Inc. (ALMS) Shares Surge 17.33% on Phase 3 Clinical Trial Data Announcement

5.001-05Benzinga

GH Research PLC Shares Surge 18.1% on FDA IND Status Update Announcement

7.512-31Globenewswire

BioAtla Secures $5 Million for Oz-V Phase 3 Clinical Trial Expenses

查看更多資訊

BCAB 事件

5/18 06:50

Context Therapeutics Amends License Agreement with BioAtla

Context Therapeutics (CNTX) announced the amendment of the company's exclusive license agreement, dated September 23, 2024, with BioAtla (BCAB). The amendment removes all future milestone and royalty obligations owed by the company for CT-202, the company's Nectin-4 x CD3 T cell engager, in exchange for a $4.5M upfront payment, and a second and final $2M payment due by August 1, 2026.

4/2 20:00

BioAtla Trading Halted, News Pending

BioAtla trading halted, news pending

3/31 16:50

BioAtla to Effect 50-for-1 Share Consolidation

BioAtla announced that it will effect a 50-for-1 share consolidation of its common stock, par value $0.0001 per share, that is expected to become effective on April 6 at 12:01 a.m. Eastern Time. The common stock will continue to trade on Nasdaq under the existing symbol (BCAB) and is expected to begin trading on a split-adjusted basis when the market opens on April 6. The share consolidation is intended to increase the per share trading price of the common stock to enable the company to regain compliance with the $1.00 minimum bid price requirement for continued listing on Nasdaq.

3/2 07:41

BioAtla Initiates Strategic Review to Maximize Shareholder Value

BioAtla's Board of Directors has initiated a formal process to explore and evaluate strategic options to maximize shareholder value, including the sale of preclinical and clinical assets, licensing transactions, strategic partnerships or other corporate transactions. Concurrently, the Company is implementing a restructuring plan to significantly reduce operating expenses, including a workforce reduction of approximately 70% and expansion of cost-containment measures. The Company intends to retain all employees essential for supporting value creation as part of its strategic review. BioAtla has engaged Tungsten Advisors as the Company's exclusive strategic financial advisor. There can be no assurance that this process will result in any such transaction. BioAtla does not intend to provide updates until the Board of Directors approves a specific action or otherwise determines whether disclosure is appropriate or required.

1/16 16:10

BioAtla Files $200M Mixed Securities Shelf

BioAtla files $200M mixed securities shelf

查看更多事件

本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。